Effect of thymopentin combined with conventional therapy on serum IL-17A, CXCL12 levels and TRPC1 expression in elderly patients with chronic obstructive pulmonary disease / 中国基层医药

ABSTRACT

Objective To investigate the effect of thymopentin combined with routine medication on serum interleukin 17A(IL-17A),chemokine 12 (CXCL12) levels and transient receptor potential channel 1 (TRPC1)expression in elderly patients with chronic obstructive pulmonary disease (COPD).Methods 156 COPD patients were selected as study objects.They were randomly divided into two groups(n =78) according to the digital table.The control group received routine treatment,and the observation group received subcutaneous injection of thymopentin on the basis of routine treatment.Before and after treatment,the CD3+,CD4+,CD8+,CD4+/CD8+ levels were tested to compare the immunologic function of the two groups.Before and after treatment,the FEV1,FEV1/FVC,PEF were tested to compare the pulmonary ventilation function of the two groups.The IL-17A,CXCL12 levels in peripheral blood and TRPC1 level in bronchoalveolar liquid before and after treatment were tested and compared between the two groups.The adverse effect was compared.Results Before treatment,the CD3+,CD4+,CD8+ and CD4+/CD8+ between the two groups had not statistically significant differences (all P ＞ 0.05),which of the control group after treatment had no significant change (all P ＞ 0.05),the CD3+,CD4+,CD4+/CD8+ of the observation group [(65.17 ± 2.39) ％,(41.06 ±2.15) ％,(1.50 ± 0.74) ％] were significantly higher than control group [(52.66 ± 2.38) ％,(32.30 ± 2.05) ％,(0.80 ± 0.81) ％] (all P ＜ 0.05),and the CDs+ of the observation group [(24.02 ± 2.23) ％] was significantly lower than control group[(32.66 ± 1.97) ％,P ＜0.05].Before treatment,the FEV1,FEV1/FVC,PEF,the IL-17A,CXCL12 levels and TRPC1 level had no statistically significant differences between the two groups(P ＞ 0.05).After treatment,the peripheral blood IL-17A [(24.18 ± 3.69) pg/mL],CXCL12 levels [(193.50 ± 2.90) pg/mL] and TRPC1 level in BALF [(7.69 ± 1.14)ng/L] in the observation group decreased significantly(P ＜ 0.05),which in the control group also decreased significantly [IL-17A (34.25 ± 3.74) pg/mL,CXCL12 (205.37 ± 3.21) pg/mL,TRPC1 (14.25 ± 1.20)ng/L] (P ＜ 0.05),which of the observation group were significantly lower than those of the control group(all P ＜0.05).The incidence rates of adverse effects of the two groups were t6.67％,12.82％,there was no statistically significant difference(P ＞ 0.05).Conclusion Thymopentin combined with conventional therapy can effectively improve the elderly COPD patients'immunologic function and pulmonary ventilation function,decrease the inflammatory factor,relieve inflammatory reaction and it is safe and effective.